144 related articles for article (PubMed ID: 31622214)
1. Discovering Therapeutic Protein Targets for Bladder Cancer Using Proteomic Data Analysis.
Bahrami S; Kazemi B; Zali H; Black PC; Basiri A; Bandehpour M; Hedayati M; Sahebkar A
Curr Mol Pharmacol; 2020; 13(2):150-172. PubMed ID: 31622214
[TBL] [Abstract][Full Text] [Related]
2. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Bellmunt J; Hussain M; Dinney CP
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
Li QQ; Hao JJ; Zhang Z; Krane LS; Hammerich KH; Sanford T; Trepel JB; Neckers L; Agarwal PK
Sci Rep; 2017 Mar; 7(1):201. PubMed ID: 28298630
[TBL] [Abstract][Full Text] [Related]
5. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer.
Yokoyama T; Enomoto T; Serada S; Morimoto A; Matsuzaki S; Ueda Y; Yoshino K; Fujita M; Kyo S; Iwahori K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2013 Jan; 132(2):472-84. PubMed ID: 22729361
[TBL] [Abstract][Full Text] [Related]
6. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
Hindy JR; Souaid T; Kourie HR; Kattan J
Future Oncol; 2019 May; 15(13):1505-1524. PubMed ID: 30977669
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
10. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor and bladder cancer.
Colquhoun AJ; Mellon JK
Postgrad Med J; 2002 Oct; 78(924):584-9. PubMed ID: 12415079
[TBL] [Abstract][Full Text] [Related]
12. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
13. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
[TBL] [Abstract][Full Text] [Related]
14. Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review.
Sanguedolce F; Russo D; Mancini V; Selvaggio O; Calò B; Carrieri G; Cormio L
Urol Int; 2019; 102(3):249-261. PubMed ID: 30463072
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation.
Sun Y; Cheng MK; Griffiths TR; Mellon JK; Kai B; Kriajevska M; Manson MM
Curr Cancer Drug Targets; 2013 Jan; 13(1):57-68. PubMed ID: 22920439
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem cells as a therapeutic target in bladder cancer.
Aghaalikhani N; Rashtchizadeh N; Shadpour P; Allameh A; Mahmoodi M
J Cell Physiol; 2019 Apr; 234(4):3197-3206. PubMed ID: 30471107
[TBL] [Abstract][Full Text] [Related]
18. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Rebouissou S; Bernard-Pierrot I; de Reyniès A; Lepage ML; Krucker C; Chapeaublanc E; Hérault A; Kamoun A; Caillault A; Letouzé E; Elarouci N; Neuzillet Y; Denoux Y; Molinié V; Vordos D; Laplanche A; Maillé P; Soyeux P; Ofualuka K; Reyal F; Biton A; Sibony M; Paoletti X; Southgate J; Benhamou S; Lebret T; Allory Y; Radvanyi F
Sci Transl Med; 2014 Jul; 6(244):244ra91. PubMed ID: 25009231
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
20. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
